TRVI — Trevi Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.64bn
- $1.44bn
- 46
- 24
- 94
- 55
Annual cashflow statement for Trevi Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -32.8 | -33.9 | -29.2 | -29.1 | -47.9 |
| Depreciation | |||||
| Non-Cash Items | 2.65 | 3.44 | 2.17 | 1.08 | 2.68 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.06 | 1.51 | -1.23 | -3.85 | 6.83 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -29 | -28.9 | -28.2 | -31.7 | -38.3 |
| Capital Expenditures | -0.032 | 0 | -0.159 | -0.137 | -0.035 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -107 | 59.6 | -21.5 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.032 | 0 | -107 | 59.4 | -21.5 |
| Financing Cash Flow Items | 2.69 | 7.09 | -0.191 | 1.52 | 61.2 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 16.7 | 20.8 | 111 | -7.91 | 61.5 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -12.3 | -8.17 | -24.2 | 19.8 | 1.7 |